Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Operating Leases (2021 - 2025)

Historic Operating Leases for Biote (BTMD) over the last 5 years, with Q3 2025 value amounting to $2.5 million.

  • Biote's Operating Leases fell 1896.89% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 1896.89%. This contributed to the annual value of $2.9 million for FY2024, which is 7202.38% up from last year.
  • Biote's Operating Leases amounted to $2.5 million in Q3 2025, which was down 1896.89% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Biote's Operating Leases peaked at $3.0 million during Q3 2024, and registered a low of $127000.0 during Q4 2021.
  • Moreover, its 5-year median value for Operating Leases was $1.9 million (2024), whereas its average is $2.0 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 141732.28% in 2022, then crashed by 1896.89% in 2025.
  • Over the past 5 years, Biote's Operating Leases (Quarter) stood at $127000.0 in 2021, then surged by 1417.32% to $1.9 million in 2022, then dropped by 12.82% to $1.7 million in 2023, then surged by 72.02% to $2.9 million in 2024, then fell by 15.16% to $2.5 million in 2025.
  • Its Operating Leases stands at $2.5 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.7 million for Q1 2025.